Gyroscope Therapeutics Holdings, a UK-based Phase 2 biotech developing gene therapies for ocular diseases, withdrew its plans for an initial public offering on Thursday. It had filed to raise $142 million in May by offering 6.8 million ADSs at a price range of $20 to $22, but postponed ahead of pricing.
The Hertfordshire, United Kingdom-based company was founded in 2016 and planned to list on the Nasdaq under the symbol VISN. Morgan Stanley, Goldman Sachs, and Citi were set to be the joint bookrunners on the deal.
